The Discounted Cash Flow (DCF) valuation of Elicera Therapeutics AB (ELIC.ST) is (172.94) SEK. With the latest stock price at 1.75 SEK, the upside of Elicera Therapeutics AB based on DCF is -9954.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.9% - 6.8% | 5.9% |
| Long-term Growth Rate | 3.0% - 3.9% | 3.4% |
| Fair Price | (421.74) - (108.17) | (172.94) |
| Upside | -24130.7% - -6263.3% | -9954.3% |